Thrombopoietin Secretion by Human Ovarian Cancer Cells

Abstract EN

The thrombopoietin (TPO) gene expression in human ovary and cancer cells from patients with ovarian carcinomatosis, as well as several cancer cell lines including MDA-MB231 (breast cancer), K562 and HL60 (Leukemic cells), OVCAR-3NIH and SKOV-3 (ovarian cancer), was performed using RT PCR, real-time PCR, and gene sequencing.

Human liver tissues are used as controls.

The presence of TPO in the cells and its regulation by activated protein C were explored by flow cytometry.

TPO content of cell extract as well as plasma of a patient with ovarian cancer was evaluated by ELISA.

The functionality of TPO was performed in coculture on the basis of the viability of a TPO-dependent cell line (Ba/F3), MTT assay, and Annexin-V labeling.

As in liver, ovarian tissues and all cancer cells lines except the MDA-MB231 express the three TPO-1 (full length TPO), TPO-2 (12 bp deletion), and TPO-3 (116 pb deletion) variants.

Primary ovarian cancer cells as well as cancer cell lines produce TPO.

The thrombopoietin production by OVCAR-3 increased when cells are stimulated by aPC.

OVCAR-3 cell’s supernatant can replace exogenous TPO and inhibited TPO-dependent cell line (Ba/F3) apoptosis.

The thrombopoietin produced by tumor may have a direct effect on thrombocytosis/thrombosis occurrence in patients with ovarian cancer.